Taken together, these data indicate that hepatic TIMP3 can slow progression of NAFLD, and tumorigenesis, at least in part, through the regulation of ADAM17 activity. This evidence concerns the gene TIMP3 and metabolic dysfunction-associated steatotic liver disease.